RecallRadar

FDA Drug recall D-0316-2021

Acyclovir Sodium Injection 500mg/10mL (50mg/mL) vial NDC 68382-048-01, For Intravenous Infusion Only MUST BE DILUTED PRIOR TO USE, packaged…

On 2021-04-07 the FDA classified a Class I recall of Acyclovir Sodium Injection 500mg/10mL (50mg/mL) vial NDC 68382-048-01, For Intravenous Infusion Only MUST BE DILUTED PRIOR TO USE, packaged… by Zydus Pharmaceuticals Usa, citing crystallization: customer complaints for crystallization in finished product.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0316-2021
ClassificationClass I
Statusterminated
Initiated2021-02-18
Published2021-04-07
Last updated2026-09-13 11:52 UTC
CompanyZydus Pharmaceuticals Usa
DistributionUS

Product

Acyclovir Sodium Injection 500mg/10mL (50mg/mL) vial NDC 68382-048-01, For Intravenous Infusion Only MUST BE DILUTED PRIOR TO USE, packaged in 10 x 10mL Single-Dose Vials per pack NDC 68382-048-10, Rx only, Manufactured by: Cadila Healthcare Ltd., Vadodara, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534.

Reason

Crystallization: customer complaints for crystallization in finished product.

Identifiers

ndc68382-048-01
ndc68382-048-10
ndc68382-049-01
ndc68382-049-10
code_infoLot#: L000126, L000127, Exp 12/31/2021

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0316-2021%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.